– Norgine B.V. today announced that the marketing authorisation for PLENVUR for bowel cleansing in adults prior to any procedure requiring a clean bowel, has been granted by the German regulatory authority. The approval was granted under the European decentralised procedure, with the UK as reference state. Norgine anticipates launch of PLENVUR in Germany later this year.
(Logo: http://mma.prnewswire.com/media/597589/Norgine_Logo.jpg )
PLENVUR is now approved for use in Australia, Austria, Belgium, Croatia, Denmark, Finland, France, Hungary, Iceland, Ireland, Italy, Norway, Portugal, Romania, The Netherlands and in the UK (using the trademark PLEINVUE™ in Austria and The Netherlands).
PLENVUR is already commercially available in the UK and Belgium.
PLENVUR is a novel, low volume (1-litre) polyethylene glycol (PEG) 3350-based bowel preparation that has been developed by Norgine to provide whole bowel cleansing.
The approvals were based on data from the Phase III clinical trial programme, consisting of three multicentre, randomised, parallel group studies: MORA, NOCT and DAYB studies.
PLENVUR (NER1006) demonstrated an acceptable safety profile in the NOCT, MORA, and DAYB phase III studies.
Norgine manufactures PLENVUR and commercialises the product through its infrastructure in Europe and Australia and through its commercial partners in the rest of the world.
Access the full media release on www.norgine.com
Media Contact:
Isabelle Jouin, T: +44-(0)1895-453643
(Immediapress – Adnkronos
Immediapress e’ un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall’ente che lo emette. Padovanews non e’ responsabile per i contenuti dei comunicati trasmessi.)